Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET

Company Participants

Carlo Tanzi - Head of IR

Eric Shaff - President & CEO

Lisa von Moltke - Chief Medical Officer

Matthew Henn - Chief Scientific Officer

David Arkowitz - CFO

Terri Young - Chief Commercial and Strategy Officer

David Ege - Chief Technology Officer

Conference Call Participants

Mark Breidenbach - Oppenheimer

Peyton Bohnsack - Cowen

John Newman - Canaccord

Ted Tenthoff - Piper Sandler

Chris Howerton - Jeffries

Chris Shibutani - Goldman Sachs

Operator

Good day, and thank you for standing by. Welcome to the Q2 2022 Seres Therapeutics, Inc. Earnings Conference Call. At lines have been placed on mute to prevent any background noise. [Operator Instructions] During today’s call there will be question-and-answer session. [Operator Instructions]

I will now turn the conference over to Dr. Carlo Tanzi, Investor Relations. Please go ahead.

Carlo Tanzi

Thank you, and good morning. Our press release for the company's second quarter 2022 financial results and a business update became available at 7 AM Eastern Time this morning and can be found on the Investors and News sections of the company's website.

I would like to remind you that, we will be making forward-looking statements, including potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a BLA filing and potential product launch, the market for SER-109, the ultimate safety and efficacy data for our products, the use of cash to fund operations and other statements, which are not historical fact. Actual results may differ materially.

Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the Risk Factor section of our recent SEC filings. Any forward-looking statements made on today’s call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so.

On today’s call with prepared remarks, I’m joined by Eric Shaff, President and Chief Executive Officer; David Arkowitz, CFO; Dr. Lisa von Moltke, Chief Medical Officer; and Dr. Matthew Henn, Chief Scientific Officer. Additional members of our management team will also be available during the Q&A.

And with that, I’ll pass the call over to Eric.

Eric Shaff

Thank you, Carlo, and good morning, everyone. We have continued to make meaningful progress across all areas of the business, including our clinical development efforts, commercial readiness, manufacturing, and in strengthening the company's balance sheet. Our top priority is SER-109, our lead microbiome therapeutic candidate for recurrent C. difficile infection.